How Long Do GLP-1 Medications Take to Work?

One of the first questions people ask about GLP-1 medications is how soon they will notice a difference. The honest answer is that the scale moves over months, not days, and the pattern is not a straight line. This guide looks at what the large trials show about timing. It is general education, not medical advice, and your own experience may differ.

Why it starts slowly

These medicines are not started at their full strength. The dose is raised in steps over a number of weeks so the body can adjust and side effects stay manageable. That means the early weeks are partly a build-up period, and the effect on appetite and weight tends to grow as the dose rises. Your clinician sets that schedule, so there is nothing to work out for yourself.

A picture of the first months

Trial data on the weight-management dose of semaglutide give a rough sense of the curve. In one follow-on trial in which participants reached the maintenance dose by about week 20, average weight had fallen by roughly 10 percent at that point (a figure worked out from the reported average weights, 107.2 kilograms falling to 96.1). Those who kept taking the medicine went on to lose roughly a further 8 percent of their week-20 weight by week 68. So loss continued well past the first five months, though more slowly than at the start.

For tirzepatide, a later analysis of the SURMOUNT-1 trial looked at when people stopped losing weight. Depending on starting BMI, the median time to reach a plateau was roughly 24 to 36 weeks, and close to 90 percent of participants had reached a plateau by week 72. Higher doses, younger age and female sex were linked to later plateaus.

Early results and later results

• Appetite often changes first. Many people report feeling full sooner before the scale moves much.
• Weight loss is not constant. Most of the change tends to come in the first 6 to 9 months, then slows and levels off.
• Some people are slower to respond. An analysis of people who had lost little by week 12 found many went on to reach 5 percent or more by week 72, so a slow start is not necessarily a verdict. Our guide to why responses vary covers this.

What can affect the timeline

• Dose and how well it is tolerated. Side effects can slow the schedule. See side effects in the big trials.
• Eating and activity. The trials paired the medicine with diet and exercise advice, and the label describes it as an addition to them.
• Starting weight and other health factors. These shape both how much and how fast.
• Staying with it. Weight tends to return when treatment stops, as described in our guide to stopping a GLP-1 medication.

Plateaus are expected

A flat stretch is a normal part of the curve, not a sign that something has failed. Our guide to why plateaus happen explains why the body settles at a new level, and what you and your clinician can do about it.

Keeping expectations kind

Averages hide a lot of variation. If you are taking one of these medicines, a conversation with your prescriber about what to expect, and when to review progress, is more useful than a number from a trial. Ask what they would consider a reasonable first check-in.

Sources

• Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA, 2021;325(14):1414-1425.
• Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Post hoc analysis, 2025.
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021;384:989-1002.
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022;387:205-216.